US Edition
Published • loading... • Updated
Gilead Boosts Immunology Pipeline with over $2 Billion Buyout of Ouro Medicines
Gilead to pay $1.675 billion upfront plus $500 million in milestones for OM336, a BCMA-targeted T cell engager advancing autoimmune disease treatment.
- On Monday, Gilead Sciences announced a definitive agreement to acquire Ouro Medicines for $1.675 billion in upfront cash, plus up to $500 million in milestone payments, to expand its inflammation pipeline.
- Gilead is diversifying beyond its core HIV and oncology franchises to target immunology and build broader growth. The acquisition secures Ouro's clinical-stage BCMAxCD3 bispecific T-cell engager, gamgertamig , for treating severe autoimmune diseases.
- Belgian partner Galapagos may lead gamgertamig development while absorbing Ouro's operating assets under advanced discussions. Keymed Biosciences, which licensed the program to Ouro, expects a total potential payout of about $320 million from the acquisition.
- OM336 is currently in Phase 1/2 studies for autoimmune indications including AIHA and ITP. The treatment received Fast Track and Orphan Drug Designation from the FDA, accelerating its regulatory pathway.
- This marks Gilead's second major M&A in a month, following the $7.8 billion takeover of Arcellx. Chief Medical Officer Dietmar Berger said the framework "complements our expanding inflammation pipeline" and reflects investment in innovative science.
Insights by Ground AI
16 Articles
16 Articles
Gilead Powers Up Its Inflammation Pipeline With Over $1.5 Billion Acquisition - Gilead Sciences (NASDAQ:GILD), Galapagos (NASDAQ:GLPG)
Gilead Sciences Inc. (NASDAQ:GILD) shares were up briefly on Tuesday as the company is expanding its inflammation portfolio through a strategic acquisition. Gilead on Monday agreed to acquire Ouro Medicines for $1.675 billion in upfront cash, with additional contingent milestone payments of up to $500 million. Strategic Acquisition Strengthens Inflammation Pipeline The acquisition adds a clinical-stage bispecific BCMAxCD3 T cell engager, OM336, …
·New York, United States
Read Full Article
Gilead’s expectation is to strengthen its drug portfolio for autoimmune diseases
·Brazil
Read Full Article
Coverage Details
Total News Sources16
Leaning Left1Leaning Right2Center9Last UpdatedBias Distribution75% Center
Bias Distribution
- 75% of the sources are Center
75% Center
C 75%
R 17%
Factuality
To view factuality data please Upgrade to Premium
